| Literature DB >> 30212456 |
Fehmida Bibi1, Isse Ali2, Muhammad Imran Naseer3, Hussein Sheikh Ali Mohamoud4, Muhammad Yasir1, Sana Akhtar Alvi1, Asif Ahmed Jiman-Fatani5, Ali Sawan6, Esam Ibraheem Azhar1,7.
Abstract
BACKGROUND: The present study was conducted to discover genetic imbalances such as DNA copy number variations (CNVs) associated with gastric cancer (GC) and to examine their association with different genes involved in the process of gastric carcinogenesis in Saudi population.Entities:
Mesh:
Year: 2018 PMID: 30212456 PMCID: PMC6136709 DOI: 10.1371/journal.pone.0202576
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinopathological features of GC patients with normal control.
| Sample ID | T | N | M | Age | Sex |
|---|---|---|---|---|---|
| 1 | 0 | 0 | 56 | Female | |
| 2 | 0 | 0 | 78 | Male | |
| 2 | 0 | 0 | 87 | Male | |
| 2 | 0 | 0 | 52 | Male | |
| 2 | 0 | 0 | 59 | Female | |
| 2 | 0 | 0 | 72 | Male | |
| 1 | 0 | 0 | 43 | Male | |
| 2 | 0 | 0 | 62 | Male | |
| 3 | 2 | 0 | 53 | Male | |
| 3 | 2 | 0 | 47 | Male | |
| 4 | 1 | 1 | 59 | Male | |
| 3 | 2 | 0 | 70 | Female | |
| 4 | 3 | 1 | 55 | Male | |
| 2 | 2 | 0 | 58 | Male | |
| 4 | 3 | 1 | 18 | Male | |
| 3 | 2 | 0 | 77 | Male | |
| 3 | 2 | 0 | 48 | Male | |
| 4 | 3 | 1 | 82 | Female | |
| 4 | 1 | 0 | 72 | Male | |
| 3 | 3 | 0 | 57 | Male | |
| 2 | 2 | 0 | 55 | Male | |
| 2 | 2 | 0 | 60 | Male | |
| 2 | 2 | 0 | 45 | Male | |
| 2 | 2 | 0 | 62 | Male | |
| 3 | 3 | 1 | 71 | Female | |
| 3 | 3 | 0 | 54 | Male | |
| 3 | 3 | 0 | 65 | Male | |
| 3 | 3 | 0 | 27 | Male | |
| 3 | 3 | 0 | 48 | Male | |
| 2 | 1 | 0 | 81 | Female | |
| 2 | 1 | 0 | 58 | Male | |
| 3 | 2 | 0 | 43 | Male | |
| 3 | 2 | 0 | 61 | male | |
| 2 | 2 | 0 | 43 | Male | |
| 2 | 2 | 0 | 60 | Male |
Summary of clinical data and abnormal array-data for gastric cancer of chromosome aberration.
| Sample.ID and age | Gender | Stage in Carcinoma | Cancer-stages/pylori | Cytoband | Copy Neutral LOH | Start | Stop | Size | GeneSymbol | |
|---|---|---|---|---|---|---|---|---|---|---|
| M | Early-stage | ES(+) | monosomy 14, monosomy 22 | |||||||
| M | Late-stage | ES(+) | ||||||||
| F | Late-stage | LS(+) | 5p15.33-p12, 7p22.3-q1 1.22, 7q22.3-q36.3, 8p23.3-p11.21, 12 p13.2-q15, 19q13.32-q13.43 | |||||||
| M | Late-stage | LS(+) | 12p13.33-p11.1, 13q14.2-q21.33, 18q21.2-q23, 20p13-p11.1, 21q21.1-q21.2, | 13q14.2-q21.33 | ||||||
| M | Late-stage | LS(+) | trisomy 4, trisomy5, trisomy 6,trisomy 14,trisomy 15, trisomy 16, 1p36.33-p32.3, 2q12.1-q23.3, 3p26.3-p11.1, 7 q22.1-q36.3, 8p23.3-p11.21, 8 p24.3-q21.11, 17q21.33-q22 | |||||||
| F | Late-stage | LS(+) | 16q11.2-q24.3, 17q21.2-q22 | |||||||
| M | Late-stage | LS(-) | trisomy 19,5p15.33-p12, 6p25.3-p11.1, 7q21.11-q22.1, 9q31.31-q34,13q31.31-q34, 16q32-q34.3, 18q13.1-q34, 20p13-p11.23 | |||||||
| M | Late-stage | LS(+) | trisomy 2, trisomy 4, trisomy 9,3p26.3-p11.1, 6 p25.3-q16.3, 8p21.3-q24.3,11q22.3-q25, 16q11.2-q24.3, 17p13.3-p11.2,18q11.2-q23, 20p13-q13.33 | 5p15.2-p15.1 | ||||||
| M | Late-stage | LS(-) | 1p36.33-q24.3, 11q11-q25 | |||||||
| M | Late-stage | LS(-) | 3p26.3-p14.2, 8q11.1-q24.3, 11p15.5-p11.12 | 3p14.2-q13.12 | ||||||
| M | Late-stage | LS(+) | trisomy 5, trisomy 12, trisomy 13,trisomy15, trisomy 17,2q11-q35.2, 4q21.11-q36.3, 7p24.1-p11.2,9q31.1-q34.3, 11p15.5-p11.12 | |||||||
| M | Late-stage | LS(+) | trisomy 6,8p23.3-p11.1, 8q21.11-q24.3, 9p24.3-p11.2,11q11-q25, 13q11-q13.3, 17q11.2-q25.3 | |||||||
| M | Late-stage | LS(+) | trisomy 5, trisomy 12, trisomy 14,trisomy 15, trisomy 17, trisomy 19,2q11-q35.2, 4q21.11-q36.3, 7p24.1-p11.2,9q31.1-q34.3, 11p15.5-p11.12 | |||||||
(Number) represent age of patient, M = male, F = female, LS = late stage, ES = early stage and (+,-) represent CNV Gain and CNV loss respectively.
Logistic regression analysis in GC cases.
| Categorised predictors | Parameter estimate | Standard error | Estimated risk (odd ratio) | 95% CI | P-value |
|---|---|---|---|---|---|
| 0.0066 | 0.07 | 1.01 | 0.97–1.04 | 0.700 | |
| -1.78 | 1.11 | 0.17 | 0.05–8.03 | 0.107 | |
| -2.24 | 0.99 | 0.63 | 0.05–8.03 | 0.025 | |
| -2.66 | 1.17 | 0.66 | 0.20–2.13 | 0.023 | |
| -1.67 | 1.59 | 2.68 | 0.26–28.08 | 0.0293 | |
| -0.72 | 1.10 | 0.49 | 0.06–4.17 | 0.510 | |
| 0.42 | 0.84 | 3.12 | 0.519–18.77 | 0.0620 | |
| -1.83 | 1.33 | 0.33 | 0.05–2.33 | 0.169 | |
| 1.4 | 1.29 | 4.05 | 0.32–50.91 | 0.0278 | |
| -0.51 | 0.50 | 0.60 | 0.23–1.60 | 0.309 |